Xbrane Biopharma AB (publ) has carried out a primary issuance of shares of approximately SEK 125 million where the subscription price was determined through an accelerated bookbuilding procedure. In connection hereto, Xbrane has concluded on a convertible bond financing implying net proceeds of SEK 225 million.

Xbrane develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 53 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during the first quarter 2023. Xbrane’s head office is in Solna, just outside Stockholm.

Pareto Securities acted as sole manager and bookrunner. Baker McKenzie acted as legal advisor with an international capital markets team consisting of Joakim Falkner, Johanna Flink, Olof Larsson, Carl Bohman and Carl Isaksson in Stockholm as well as Adam Farlow, James Tanner and Madeleine Barrow in London.

Explore Our Newsroom